Search Results 841-850 of 10439 for total t4

  1. A Study of Standard Systemic Therapy with or without Definitive Treatment in Treating Participants with Metastatic Prostate Cancer - Mayo Clinic

    Participation eligibility · Patients must be ≥ 18 years of age. · Patients must have a complete physical examination and medical history within 28 days prior to ...

  2. Publications - TK A. Kile, M.D. - Mayo Clinic

    30-Day Outcomes for Total Ankle Arthroplasty in Patients With Anemia. Foot Ankle Int. 2021 Nov; 42 (11):1463-1468 Epub 2021 June 10. View PubMed; Sagherian BH ...

  3. PRE-I-SPY Phase I/Ib Oncology Platform Program - Mayo Clinic

    ... overall goal of moving promising drug regimens. Participation ... who have undergone bilateral oophorectomy, total hysterectomy, or bilateral tubal

  4. Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Tool - Mayo Clinic

    The purpose of this study is to field test and update an existing conversation aid prototype designed to support shared decision making in the diagnosis and ...

  5. Study Of Lurbinectedin In Combination With Doxorubicin Versus Doxorubicin Alone As First-line Treatment In Participants With Metastatic Leiomyosarcoma - Mayo Clinic

    Total bilirubin ≤ ULN or direct bilirubin ≤ ULN if total bilirubin is > ULN;. Albumin ≥ 3.0 g/dL;. Calculated creatinine clearance (CrCL) ≥ 30 mL/min ...

  6. FOG-001 In Locally Advanced Or Metastatic Solid Tumors - Mayo Clinic

    * Osteoporosis, which is defined as a T-score of ≤-2.5 at the lumbar spine (L1 - L4), left (or right) femoral neck or left (or right) total hip as determined ...

  7. Ultrasound as Surrogate Diagnostic Tool for ACL Injury - Mayo Clinic

    For Aim 2, 40 total lower extremities will be recruited for 3D US imaging of the ACL at their pre-surgical clinical visit. This will include the injured ...

  8. Mayo Clinic

    Accordingly, the total investment return is reported in the consolidated statements of activities in two categories. The investment return allocated to current ...

  9. Digestive Diseases Clinical Trials - Medical Professionals

    The primary study hypothesis is that pembrolizumab will prolong progression-free survival (PFS) or overall survival (OS) compared to current SOC chemotherapy.

  10. A Study to Compare Tisagenlecleucel vs. Standard of Care in Adult Patients with Aggressive B-cell Non-Hodgkin Lymphoma - Mayo Clinic

    Total bilirubin ≤ 1.5 x ULN with the exception of patients with Gilbert syndrome who may be included if their total bilirubin is ≤ 3.0 × ULN and direct ...